The Latest Cardiac and Vascular News
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) announces the expiration of Boston Scientific Corporation’s (“BSC”) exclusive right to negotiate for distribution of REVA’s coronary and peripheral bioresorbable scaffolds. BSC’s right to negotiate was available under a 2007 agreement that would have […]
Boston Scientific decides it’s too risky and that there are “bigger” problems to deal with. Boston Scientific to end Renuvia bioresorbable coronary stent program JULY 31, 2017 BY FINK DENSFORD, MassDevice Boston Scientific (NYSE:BSX) is looking to terminate its Renuvia bioresorbable coronary stent program, according to a Minneapolis Star Tribune report. The move comes after […]
Boston Scientific warns on fluke S-ICD death JULY 28, 2017 BY BRAD PERRIELLO , MassDevice Boston Scientific (NYSE:BSX) last month alerted physicians after learning of a fluke incident involving its S-ICD pacemaker, in which a patient died when the device’s memory was corrupted by radiation. In a June letter to physicians, Marlborough, Mass.-based Boston […]
MARLBOROUGH, Mass., July 27, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.257 billion during the second quarter ended June 30, 2017. This represents growth of 6 percent on a reported basis and 7 percent on an operational basis (excludes the impact of changes in foreign currency exchange rates), all compared to […]
NEWS PROVIDED BY Boston Scientific Corporation 08:30 ET MARLBOROUGH, Mass., July 5, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2017 on Thursday, July 27, 2017 at 8:00 a.m. EDT. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan […]
MARLBOROUGH, Mass., June 27, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to provide an overview of its business and long-term growth strategies. Chairman of the Board and Chief Executive Officer Mike Mahoney will discuss how the […]
MARLBOROUGH, Mass., May 9, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The approval includes new features in the Resonate devices including SmartCRT technology with Multisite Pacing […]
MARLBOROUGH, Mass., May 3, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be featured at the 38th Annual Scientific Sessions of the Heart Rhythm Society in Chicago on May 10-13. Notably, the post-market approval data collected on […]
MARLBOROUGH, Mass., April 27, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.160 billion during the first quarter ended March 31, 2017. This represents growth of 10 percent compared to the prior year period on a reported and operational basis (calculated on a constant currency basis). The company reported […]
MARLBOROUGH, Mass., March 30, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices, for $435 million in up-front cash. The Symetis portfolio includes the ACURATE TA™ and ACURATE neo/TF valve* […]
